Effective Cancer therapy is a huge unmet medical need. Consequently, much research in the public and private sector is geared at addressing this unmet medical need. However, the success of obtaining cancer chemotherapies have not matched the efforts expanded and one metric that demonstrates the difficulty in this therapeutic area is the relatively higher rates of attrition of compounds that enter clinical trials in humans. Only 5% of compounds that the top ten drug companies introduced into clinical development (First in Man) between the years 1990 to 2000 were approved by US and/or European Regulatory Authorities (Kola and Landis, 2004; Figure 1 ). This can be compared to an average 11% across all therapeutic areas and approximately 20% in Cardiovascular Diseases. The major reason for the high attrition is lack of efficacy, and this attrition occurs in late phase II or Phase III.
It is also known that genetic heterogeneity is an important characteristic of cancers. Hence, it is important not to treat any specific Cancer-type as a homogenous disease. This feature also contributes to the complexity of developing therapeutics for Cancer since these have to be trailed in many different types of Cancers. Also phase II clinical trails are spectacularly unpredictive of outcomes from phase III clinical trails. Genetic heterogeneity of tumors may thus also be an important contributor to the high attrition rates of compounds.
This session will deal with evolving technologies aimed at identifying patients who are more likely to respond to specific therapeutic agents and in this manner recognizes the differences in specific-types of tumors. Also the use of molecular/genetic signatures may be an important tool that mitigates the high attrition rates of Cancer chemotherapeutics since it can impact both efficacy and safety of compounds.
